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Preface 
 
The work comprised in this thesis is the result of collaboration between Department 
of Rheumatology, Department of Nephrology, and Department of Cardiology, 
Aalborg University Hospital and Department of Rheumatology, the North Denmark 
Regional Hospital, DK, during the period 2013-2016. This dissertation is constructed 
with an opening introduction followed by the hypotheses and aims of the thesis, a 
description of the methodological approaches, presentation of the results and 
concluded in a summarizing discussion.  
The work is to the best of my knowledge original, except where acknowledgement 
and references are made to previous work. 
The thesis is based on the three papers listed below, which are referred to in roman 
numerals in the text. The manuscripts are enclosed in the Appendix. 
 
 
Study I 
Salome Kristensen, Jeppe Hagstrup Christensen, Erik Berg Schmidt, Jens Lykkegaard 
Olesen, Martin Berg Johansen, Kristian Arvesen, Annette Schlemmer 
Assessment of enthesitis in patients with psoriatic arthritis using clinical 
examination and ultrasound. Accepted for publication in Muscles Ligaments 
Tendons J., 2016. 
 
Study II 
Salome Kristensen, Erik Berg Schmidt, Annette Schlemmer, Claus Rasmussen, 
Martin Berg Johansen, Jeppe Hagstrup Christensen 
Beneficial effect of n-3 PUFA on inflammation and analgesic use in psoriatic 
arthritis – a randomised, double-blind, placebo-controlled trial. Submitted to 
Scand. J. Rheumatol., 2016. 
 
Study III 
Salome Kristensen, Erik Berg Schmidt, Annette Schlemmer, Claus Rasmussen, 
Esther Lindgreen, Martin Berg Johansen, Jeppe Hagstrup Christensen 
The effect of marine n-3 polyunsaturated fatty acids on cardiac autonomic and 
hemodynamic function in patients with psoriatic arthritis: a randomised, double-
blind, placebo-controlled trial. Submitted to Lipids Health Dis., 2016 
 
 
 
The PhD thesis is submitted to the Faculty of Medicine, 
Aalborg University, Denmark, August 2016 
 
 
 
Marine n-3 Polyunsaturated Fatty Acids in Psoriatic Arthritis – Inflammation and 
Cardiac Autonomic and Hemodynamic Function 
4 
 
Acknowledgement  
 
My PhD thesis has come to an end and I cannot express the excitement following the 
scientific ideas, the hope for positive results, disappointments with each failed 
attempt, the tiredness after long days spent behind the desk, and the joy with data 
synthesis. This thesis would have been impossible without the help and support from 
people, to whom I am indebted. Firstly, I would therefore like to thank my main 
supervisor Jeppe Hagstrup Christensen for his endless support, enthusiasm, 
knowledge and for providing me the opportunity to pursue my goals into the field of 
medical science. My deepest admiration and thankfulness goes to Erik Berg Schmidt 
for his unique expertise, knowledge and scientific input along with his great 
excitement and interest in my studies. I would also like to express my sincere gratitude 
to Annette Schlemmer for her inspiring guidance, valuable scientific discussions and 
for always being there for me as a mentor. 
I am also grateful for the excellent contribution from remaining co-authors Claus 
Rasmussen, Martin Berg Johansen, Esther Lindgreen and Kristian Bakke Arvesen. 
Furthermore, the head of the Department of Rheumatology in Aalborg, Vivian Kjær 
Hansen deserves special thanks for support through the years of my PhD study. 
My greatest appreciation goes to Charlotte Mose Skov, Kirsten Holdensen, Vinie 
Mellergaard, Rikke B. Eschen, Annette Andreasen, Birthe Thomsen, Heidi Mächler 
Christensen, Jette Kragh, Birgitte Rasmussen, Xenia Schlemmer, Britt Mejer 
Christensen and Hanne Madsen for invaluable laboratory assistance, excellent work 
participating in the examinations, data management and proofreading. 
The enthusiasm and kindness from the patients participating in the studies have been 
a great source of inspiration and I will always be thankful for their effort. 
The research for this thesis would not have been possible without the financial 
generosity of the Research Foundation of Aalborg University Hospital, The Medical 
Research Foundation of the North Denmark Region, The Danish Rheumatism 
Association, The Danish Psoriasis Foundation, The Aage Bang Foundation, Abbvie 
Foundation, Heinrich Kopp’s Foundation and Jacob Madsen and wife Olga Madsen 
Foundation. In addition, Marine Pharma, Norway, kindly delivered the capsules of 
marine n-3 PUFA and olive oil. 
Finally, my deepest thankfulness goes to my wonderful husband and children; this 
would not have been possible without their support and encouragement. 
 
Salome Kristensen, 2016 
 
 
  
5 
 
List of abbreviations  
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CI: Confidence interval;  
BP: Blood pressure;  
AIx: Aortic augmentation index 
BMI: Body mass index 
NSAID: Nonsteroidal anti-inflammatory drugs 
DMARDs: Disease-modifying antirheumatic drugs  
CASPAR: Classification criteria for psoriatic arthritis 
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GS: Grey scale 
VAS: Visual analogue scale  
HAQ: Health assessment questionnaire  
DAS66/68-CRP: 66/68 joint count disease activity score based on CRP 
ASDAS: Ankylosing spondylitis disease activity score  
BASDAI: Bath ankylosing spondylitis disease activity index  
BASMI: Bath ankylosing spondylitis metrology index  
LEI: Leeds enthesitis index  
SPARCC: Spondyloarthritis research consortium of Canada enthesitis index 
MASES: Maastricht ankylosing spondylitis enthesitis score 
PASI: Psoriasis area and severity index  
GCP: Good Clinical Practice  
ACR: American College of Rheumatology 
ACR20/50/70: American College of Rheumatology response criteria with > 
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RA: Rheumatoid arthritis 
PG: Prostaglandin 
TX: Thromboxane 
LTB4: Leukotriene B4 
LTB5: Leukotriene B5 
5-HETE: 5-hydroxyeicosatetraenoic acid  
5-HEPE: 5-hydroxyeicosapentaenoic acid  
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TNF-α: Tumour necrosis factor alpha 
ICC: Intraclass correlation coefficient  
COX: Cyclooxygenase 
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English summary 
 
Psoriasis occurs in 1-2% of the population. Depending on the population studied, 
psoriatic arthritis (PsA) may occur in 6-39% of individuals with psoriasis. PsA is a 
multigenic inflammatory disease involving synovial tissue, axial joint, entheseal sites, 
and the skin with a wide clinical range and diverse outcomes.  
Enthesitis is a hallmark feature of PsA and has been proposed as an important area of 
assessment and outcome. Several assessment tools for enthesitis have been developed, 
although there is concerns about which particular scoring system is optimal.  
It is also important to recognize the long-term adverse outcomes related to associated 
comorbidities such as cardiovascular disease (CVD). Thus, several studies have 
indicated that chronic inflammation may impair autonomic cardiac regulation leading 
to a decrease in heart rate variability (HRV). A low HRV has been identified as an 
independent predictor of coronary heart disease, as well as malignant ventricular 
arrhythmias and sudden cardiac death. Previous studies have also revealed an 
increased arterial stiffness measured by pulse wave velocity (PWV) in patients with 
PsA.  
Marine n-3 polyunsaturated fatty acids (PUFA) may reduce the incidence of CVD in 
part by increasing HRV and decreasing PWV. In addition, n-3 PUFA have anti-
inflammatory effects and thus could have the potential to reduce inflammation, joint 
pain and consumption of non-steroidal anti-inflammatory drugs (NSAID) in patients 
with PsA.  
 
This thesis is based on three studies of patients with established PsA aiming at 
investigating the effect of marine n-3 PUFA on clinical symptoms and selected 
measures of inflammation, cardiac autonomic and hemodynamic function in these 
patients. 
 
Study I aimed to investigate whether training in standardised assessment of enthesitis 
in PsA is able to improve interobserver variation. Furthermore, ultrasonography (US) 
and clinical assessment of enthesitis were compared in detecting abnormalities. The 
results of this study showed significant reduction in interobserver variation with 
training in standardised enthesitis scoring systems, suggesting training sessions of 
clinicians before assessment of enthesitis in daily practice. US revealed more 
advanced stages of enthesitis, such as enthesophytes and erosions, which were not 
detected by clinical examination.  
 
To investigate effects of marine n-3 PUFA on clinical outcomes, important 
biochemical markers and cardiovascular risk in patients with PsA a randomized 
placebo-controlled trial was undertaken (Study II and III). One-hundred and forty-five 
patients were enrolled and randomized to a supplement with either 3 g of marine n-3 
PUFA (6 capsules of fish oil) or 3 g of olive oil daily for 24 weeks. A total of 133 
patients (92%) completed the study. The difference in the outcomes between baseline 
and 24 weeks was analysed within and between the two supplemented groups. 
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In Study II, the effects of n-3 PUFA supplementation on outcome measures for disease 
activity, NSAID and paracetamol consumption and inflammation quantified as 
leukotriene formation from stimulated granulocytes was examined. The n-3 PUFA 
supplemented group showed improvement in outcome measures for disease activity, 
though without reaching a significant difference between the groups. However, use of 
NSAID and paracetamol was significantly reduced from baseline to week 24 in the n-
3 PUFA group; also when compared with the control group. Furthermore, there was 
a significant decrease in leukotriene B4 (LTB4) formation from activated granulocytes 
in the n-3 PUFA group compared with controls. The results indicate a beneficial effect 
of n-3 PUFA on joint inflammation and pain. 
In Study III, the aim was to investigate the effect of marine n-3 PUFA on cardiac 
autonomic function assessed by HRV, blood pressure (BP), PWV and central BP. 
After 24 weeks of supplementation, there was a trend towards increase in HRV in the 
intention to treat analysis and a significant increase in HRV in the compliant patients. 
This finding may suggest a protective effect of n-3 PUFA against CVD in this 
population. There were, however, no changes in BP, PWV or central BP between 
supplements.  
 
 
In conclusion, this thesis showed that training in enthesitis assessment improves the 
interobserver variation and evaluation of patients, and that supplementation with n-3 
PUFA resulted in a reduction in analgesic use, decrease in LTB4 formation and a 
beneficial effect on cardiac autonomic function in patients with PsA. The 
investigation of enthesitis underlines the importance of training in enthesitis 
assessment before using the scoring systems in clinical setting. Subsequently, the 
investigators of Study II and III were trained in enthesitis score before conduction of 
the study. The improvement in cardiac autonomic function and the reduction in 
NSAID use after supplementation with n-3 PUFA may be relevant in patients with 
PsA because of their higher risk of CVD compared to healthy individuals. The large 
number of participants completing the study underlines the applicability of n-3 PUFA 
to clinical practice. Further studies are, however, required to confirm the clinical 
findings of the present study and to clarify the possible use of marine n-3 PUFA in 
patients with PsA.   
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Dansk resume 
 
Psoriasis forekommer hos 1-2 % af befolkningen. 6-39 % af disse patienter udvikler 
psoriasis arthrit (PsA). PsA er en inflammatorisk sygdom, ofte involverende hud, led, 
entheser (senetilhæftninger) og rygsøjlen.  
Enthesitis er en af kardinalmanifestationerne ved sygdommen, og der er udviklet en 
række målemetoder til vurdering af enthesitis hos patienterne. Der eksisterer dog 
hidtil ingen konsensus om, hvilke målemetoder, der er mest optimal for patienter med 
PsA. Samtidig gør sygdommens komplekse billede behandlingsstrategien vanskelig. 
PsA patienter har ofte utilstrækkelig effekt af de eksisterende lægemidler og behov 
for langvarig behandling med non-steroidal anti-inflammatory drugs (NSAID). Hertil 
kommer, at patienter med PsA har risiko for co-morbiditeter såsom 
hjertekarsygdomme.  
Inflammationen hos patienter med PsA synes at påvirke den autonome hjertefunktion. 
Til opsporing af risiko for hjertekarsygdom og påvirkning af hjertets autonome 
funktion kan Heart rate variability (HRV) anvendes. HRV er en noninvasiv metode 
og generelt afspejler en høj HRV øget vagusaktivitet og dermed beskyttelse mod 
hjertekarsygdomme og pludselig hjertedød. Tidligere studier har fundet nedsat HRV 
hos patienter med PsA. Samtidig har studier af patienter med PsA også påpeget højere 
risiko for øget karstivhed målt ved non-invasive metoder som Pulse Wave Velocity 
(PWV). Dog foreligger endnu ingen behandlingsstrategi for forebyggelse af 
hjertekarsygdomme hos patienter med PsA.  
Fiskeoliens n-3 flerumættede fedtsyrer (PUFA) har vist gunstig effekt på risiko for 
hjertekarsygdomme målt ved HRV og PWV i forskellige patientgrupper. Herudover 
har n-3 PUFA i nogle studier medført reduktion i ledsmerter, forbrug af 
smertestillende midler og inflammation hos patienter med arthrit. 
 
Denne afhandling er baseret på tre studier omhandlende patienter med PsA.  
Studie I undersøgte effekten af undervisning og standardiseret træning i enthesitis 
score samt fordele ved brug af ultralydsundersøgelse til vurdering af enthesitis. 
Resultaterne viste signifikant forbedring af interobservatør variationen ved enthesitis 
score efter træning, hvilket nødvendiggør træning forud for brug af enthesitis scores i 
daglig klinik. Ved ultralydsundersøgelse blev der fundet mere fremskredne stadier af 
enthesitis, som ikke kunne detekteres ved den kliniske undersøgelse. Kommende 
studier skal belyse, hvilken betydning disse fund ved ultralydsundersøgelse kan 
tillægges.  
Et randomiseret, dobbelt-blindet og placebokontrolleret forsøg (studie II og III) blev 
gennemført til vurdering af effekten af n-3 PUFA hos patienter med PsA. 
Sygdomsaktivitet, NSAID forbrug, biokemiske markør samt risiko for 
hjertekarsygdomme blev målt. 145 patienter deltog i forsøget og 133 (92%) 
gennemførte forsøget. Forskellen i målinger fra baseline til uge 24 er udregnet for 
hver forsøgsgruppe og sammenlignet mellem de to forsøgsgrupper. 
Studie II belyste effekten af n-3 PUFA på sygdomsaktivitet og forbrug af NSAID og 
paracetamol. 24 ugers tilskud af n-3 PUFA medførte signifikant fald i parameter for 
sygdomsaktivitet i gruppen der indtog n-3 PUFA, dog var dette fund ikke signifikant 
Marine n-3 Polyunsaturated Fatty Acids in Psoriatic Arthritis – Inflammation and 
Cardiac Autonomic and Hemodynamic Function 
10 
 
sammenlignet med kontrolgruppen. Endvidere resulterede n-3 PUFA indtag i 
reduktion af NSAID- og paracetamolforbrug samt nedsat produktion af den 
proinflammatoriske leukotrien B4 (LTB4). Resultaterne fra dette studie påpeger 
således mulig gavnlig effekt af n-3 PUFA på inflammation og ledsmerter hos patienter 
med PsA 
Studie III havde til formål at undersøge effekten af n-3 PUFA på hjertets autonome 
funktion målt ved HRV og karstivhed målt ved PWV. Resultaterne fra dette studie 
viste tendens til forbedring i HRV ved intention to treat analyserne. Denne stigning i 
HRV var signifikant hos patienter, der havde indtaget mere end 85% af deres n-3 
PUFA forsøgskapsler (per-protocol analyserne). Disse fund antyder gunstig effekt af 
fiskeolien n-3 PUFA på risiko for hjertekarsygdom hos patienter med PsA. Studiet 
viste dog ingen signifikante ændringer i PWV efter n-3 PUFA tilskud. 
 
 
Sammenfattende viste denne afhandling, at undervisning og træning i enthesitis 
undersøgelse kan forbedre interobservatør variationen; og at n-3 kan medføre 
reduktion i NSAID og paracetamolforbrug, mindske LTB4 dannelse og kan have 
gunstig effekt på hjertets autonome kontrol hos patienter med PsA.  
På baggrund af resultaterne fra studie I, blev undersøgelse af enthesitis i studie II og 
III udført af trænede læger, og den samme læge gennemførte kliniske undersøgelser 
ved studiets start og afslutning. Herudover er afhandlingen baseret på det hidtil største 
interventionsstudie med n-3 PUFA hos patienter med PsA. Effekten på hjertets 
autonome kontrol og den NSAID-besparende virkning gør n-3 PUFA særlig gavnligt 
hos patienter med psoriasis arthrit med kendt højere risiko for hjertekarsygdomme end 
baggrundsbefolkningen. Den store tilslutning til forsøget med 145 inkluderede 
patienter og det høje antal patienter, der gennemførte forsøget, fremhæver 
anvendeligheden af n-3 PUFA i behandlingsstrategien for patienter med PsA. Der er 
behov for fremtidige studier til at bekræfte resultaterne fra denne afhandling og 
belyse, hvilke undergruppe af patienter med PsA, der har den største gavn af n-3 
PUFA på hjertekarsygdomme og inflammation. 
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CHAPTER 1. BACKGROUND 
Psoriatic arthritis 
 
Globally, the prevalence of psoriasis varies based on geographic location, ranging 
from 0 % in Latin America to approximately 3 % in Denmark for all ages (1). Overall, 
psoriasis is more common in regions located farther from the equator, such as Europe 
and Australia, than in those closer to the equator, such as Tanzania, Sri Lanka, and 
Taiwan (1). Psoriatic arthritis (PsA) is a chronic inflammatory joint disease occurring 
in 6-39 % of patients with psoriasis and the prevalence in the general population is 
approximately 0.2% (2–4). Historically, PsA was thought to be represented as a co-
existence of psoriasis and rheumatoid arthritis (RA), but the American Rheumatism 
Association recognised the independent existence of PsA in 1964 (5). PsA is now 
considered as a part of the spondyloarthritis family with a wide clinical spectrum and 
outcome (6).  
Enthesitis is suggested to underpin most if not all of the manifestations of PsA (7). 
Assessment of enthesitis is therefore highly recommended in the evaluation of disease 
activity in daily practice and clinical trial. Several scoring systems have been 
developed, but currently no “gold standard” exists for evaluation of enthesitis in 
patients with PsA.  
The diversity of PsA symptoms complicates the management of the disease. 
Treatment recommendations from the European League Against Rheumatism 
(EULAR) propose NSAID as first choice treatment then, if necessary, disease-
modifying antirheumatic drugs (DMARDs), including biological treatments (8) may 
be added. Nevertheless, treatment of PsA is often unsatisfactory and approximately 
half of the patients experience an insufficient response (9,10).  
Furthermore, PsA is associated with comorbidities such as CVD (11,12) with few data 
and no consensus on prevention and treatment.  
 
 
Enthesitis in psoriatic arthritis 
 
Enthesitis is defined as inflammation at the insertion of tendons, ligaments, and 
capsules into bone. Recent registry data and clinical trials have reported enthesitis in 
up to 50% of PsA patients (13). The Seventh International Consensus Conference on 
Outcome Measures in Rheumatology (OMERACT) recognized the clinical 
importance of enthesitis, in addition to the assessment of peripheral joint disease, in 
PsA (14). Conventionally, enthesitis has been assessed by clinical examination and 
several enthesitis-scoring measures exist (Table 1-1). All of these involve a standard 
palpation approach, i.e., applying ~ 4 kg/cm2 pressure (enough to blanch the tip of the 
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examiner’s fingernail), and ascertaining the presence, absence or, in some indices, the 
severity of tenderness.  
The Mander index (15) was the first published instrument for scoring enthesitis and 
required assessment of 66 sites and is criticised for being time consuming and failing 
to distinguish enthesitis sites from fibromyalgia tender points (16). Therefore, The 
Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) (17) and The 
Spondyloarthritis Research Consortium of Canada (SPARCC) index (18) has been 
developed and used in clinical trials of patients with PsA. However, these indices have 
not been extensively validated in PsA (19).  
Recently, the Leeds enthesitis index (LEI) has been developed for measuring 
enthesitis in patients with PsA and has the advantage of including only six sites, all 
easily accessible (20). The LEI has showed closest correlation with other disease 
activity measures and good sensitivity to changes. 
 
 
 MASES SPARCC LEI  
 
First costochondral R, L   
Seventh costochondral R, L   
Supraspinatus insertion  R, L  
Lateral epicondyle humerus  R, L R, L 
Medial epicondyle humerus  R, L  
Posterior superior iliac spine R, L   
Anterior superior iliac spine R, L   
Iliac crest R, L   
Fifth lumbar spinous process X   
Achilles tendon R, L R, L R, L 
Greater trochanter  R, L  
Medial condyle femur   R, L 
Insertion plantar fascia  R, L  
Quadriceps insertion patella  R, L  
Inferior pole patella  R, L  
(Tibial turbercle)  (R,L)  
 
Table 1-1 Enthesial sites assessed in outcome measures for enthesitis. MASES: 
Maastricht Ankylosing Spondylitis Enthesitis Score; SPARCC: Spondyloarthritis 
Research Consortium of Canada enthesitis index; LEI: Leeds enthesitis index; R: 
right; L: left.  
 
Imaging modalities such as ultrasonography (US) have been suggested to improve 
entheseal disease assessment. Studies have shown that US indices for enthesitis are 
more sensitive than clinical examination (21,22). The OMERACT US Specialist 
Interest Group reached agreement on US definition of enthesitis and its elementary 
components to ensure a higher degree of homogeneity and comparability of results 
between studies and daily clinical work (23). However, the value of US findings at 
the enthesis is not investigated fully. Although Doppler sign at the enthesis is found 
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more frequently in patients with PsA, as compared with healthy controls (24), it can 
also be seen in patients with RA (25). Bone changes such as enthesophytes and 
erosions seen on US may also be found as degenerative changes in weight-bearing 
entheses (26). Furthermore, the application of US in daily practice in patients with 
PsA is limited by the time required to examine multiple sites of enthesitis.  
Since clinical enthesitis is a hallmark feature of PsA, there is a need for improvement 
of clinical assessment of enthesitis and evaluation of the benefits of US as an outcome 
measure in daily practice.  
 
Psoriatic arthritis and the risk of cardiovascular disease 
 
Accelerated atherosclerosis due to inflammation, and autonomic dysfunction can both 
play a role in the pathogenesis of CVD in patients with PsA in addition to conventional 
risk factors for CVD such as smoking, hypertension, hypercholesterolemia and 
diabetes mellitus (27). Impaired autonomic cardiac regulation (28,29) and increased 
arterial stiffness have thus been identified as risk markers for CVD in patients with 
PsA (30–32).  
Patients with psoriasis and/or PsA have an increased risk of myocardial infarction, 
stroke, and cardiovascular death (33) and CVD is the most common cause of death in 
these patients (34).  
 
1.1. Cardiac autonomic dysfunction 
 
Several studies have indicated that chronic inflammation may impair autonomic 
cardiac regulation leading to a decrease in heart rate variability (HRV) (28,29). The 
autonomic nervous system consists of the sympathetic and the parasympathetic 
systems with opposing functions. While the sympathetic system increases heart rate 
(HR), myocardial contractility and peripheral resistance, the parasympathetic system 
slows HR. This antagonism is mediated by their neurotransmitters, catecholamines 
and acetylcholine.  
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Figure 1-1 Vagal nerve control of the heart and circulation 
 
 
Measurement of HRV has emerged as a simple, non-invasive method to evaluate the 
sympatho-vagal balance within the autonomic control of sinus node function (35). 
During sinus rhythm HR and its inverse, the RR interval, vary from beat-to-beat in 
response to changes in autonomic function. HRV describes this beat-to-beat variation 
and can be obtained from Holter recordings during a short time period or from 24-h 
or longer periods. It can be analysed in the time domain indices (used in this thesis) 
and frequency domain or by non-linear methods. Time domain HRV indices are 
derived directly from the RR interbeat intervals or from differences between 
successive RR-intervals. Frequency domain analyses of the HR fluctuation has 
identified a low frequency band reflecting both sympathetic and parasympathetic 
influences and a high frequency band reflecting parasympathetic influence. An 
attenuated HRV reflects an increased sympathetic or a decreased vagal modulation, 
and a low HRV has been identified as an independent predictor of both coronary heart 
disease (36) as well as malignant ventricular arrhythmias and sudden cardiac death 
(11–15).  
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Figure 1-2 HRV recordings with SphygmoCor Technology illustrating the variation 
in heart rate measured over short time.  
 
Interactions between the autonomic nervous system and the immune system have been 
reviewed recently and a direct autonomic innervation and non-synaptic 
communication with the immune system has been shown (42,43). In particular, the 
vagal nerve is sensitive to pro-inflammatory cytokines, such as interleukin-1 (IL-1), 
IL-6 and tumour necrosis factor alpha (TNF-α), all substances released by 
macrophages and other immune cells (44). The vagal nerve is considered to interact 
with the immune system both through its afferent (activation of the hypothalamic–
pituitary–adrenal axis) and efferent fibres (release of acetylcholine at the distal end of 
the vagal nerve, which inhibits the release of pro-inflammatory cytokines such as 
TNFα by macrophages) (45). 
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Figure 1-3 The inflammatory reflex; Vagus nerve afferent and efferent control of the 
heart and the immune system. Ach: Acetylcholine; ChAT+ T cells: choline 
acetyltransferase-expressing T cells; α7nAChRs: α7-nicotinic ACh receptors; β2AR: 
β2-adrenergic receptors. 
 
Abnormalities in the autonomic nervous system as well as cardiovascular autonomic 
dysfunction have been reported in patients with inflammatory rheumatic diseases (46). 
A recent study in patients with RA thus showed that autonomic dysfunction 
determined by HRV was related to elevated intrathecal proinflammatory IL-β1 levels 
(47). However, only few minor studies have investigated short term HRV and 
demonstrated attenuated HRV in patients with PsA (48–50) and Table 1-2 shows the 
published studies investigating HRV in patients with PsA. In a small study with 20 
PsA patients Syngle et al. observed improvement in autonomic dysfunction after 
treatment with synthetic DMARDs for 3 months (51). A likely explanation for a low 
HRV in patients with PsA is the presence of systemic inflammation leading to a 
decreased parasympathetic regulation of cardiac autonomic tone (52,53).  
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Table 1-2 Characteristic of studies investigating Heart rate variability in patients with 
psoriatic arthritis. HRV: heart rate variability; PsA: psoriatic arthritis; n: study 
sample size; DMARD: disease modifying anti-rheumatic drug; ACR20/50/70: 
American College of Rheumatology response criteria with > 20%/50%/70% 
improvement; DAS28: disease activity score, 28 joint count. SDNN: standard 
deviation of all normal RR intervals in the 5 min recording; pNN50: percentage of 
successive RR-interval differences > 50 ms. 
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1.2. Arterial stiffness 
 
Endothelial inflammation and atherosclerosis cause injury to the endothelium and can 
proceed to intimal thickening with a decrease in vascular wall contractile elements. 
The resultant arterial stiffness is characterised by increased vascular collagen 
formation, calcification and breakdown of elastin (56). Arterial stiffness has been 
recognised as an independent predictor of CVD (57). Arterial stiffness can be 
determined non-invasively by pulse wave velocity (PWV) using applanation 
tonometry. PWV is defined as the velocity of the arterial pulse along the vessel wall, 
as an indicator of arterial distensibility (58). Increased carotid-femoral PWV, aortic 
augmentation index (AIx) and central systolic pressure are all considered independent 
risk factors for arterial stiffness and CVD (57,59).  
 
 
 
 
Figure 1-4 Illustration of pulse wave velocity measurements performed with the 
Sphygmocor system 
A meta-analysis of eleven longitudinal studies investigated the influence of central 
haemodynamic indices on cardiovascular outcomes, cardiovascular mortality and all-
cause mortality in 5648 patients (59). Several populations such as patients with 
hypertension, end-stage renal disease, coronary artery disease, and subjects from 
general population were included. The authors found that the age- and risk-factor-
adjusted pooled relative risk of total CV events was 1.1 for a 10 mmHg increase of 
central systolic pressure, 1.1 for a 10 mmHg increase of central pulse pressure, and 
1.3 for a 10% absolute increase of central augmentation index (AIx). Furthermore, 
they found that a 10% increase of central AIx was associated with a relative risk of 
1.4 for all-cause mortality.  
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Chronic inflammatory diseases have been associated with arterial stiffness (60–63). 
This might be caused by inflammatory cytokines promoting leucocyte infiltration into 
the arterial wall, causing endothelial inflammation and upregulation of angiotensin 
type 1 receptors leading to vasoconstriction and hypertension (64,65).  
PWV, in patients with RA, systemic lupus erythematosus and vasculitis is increased 
compared with controls (60,61,66). However, PWV and AIx were only increased in 
patients with active disease and not during remission (60,67). In a subanalysis of 9 
patients with RA receiving anti-tumor necrosis factor-α, treatment reduced aortic 
stiffness to levels comparable to healthy individuals (66). Table 1-3 demonstrates the 
studies investigating PWV in patients with PsA. Further studies in patients with PsA 
are needed to clarify whether disease control and treatment can reverse the arterial 
stiffness.  
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Table 1-3 Characteristic of studies investigating pulse wave velocity in patients with 
psoriatic arthritis. n: study sample size; PsA: psoriatic arthritis; PWV: pulse wave 
velocity.   
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Marine n-3 Polyunsaturated Fatty Acids 
 
There are two types of PUFA, the n-6 and n-3 PUFA. n-6 PUFA are primarily found 
in plant oils, in which the main n-6 PUFA is linoleic acid (LA; 18:2n-6). Linoleic acid 
is elongated and desaturated in humans to form arachidonic acid (AA; 20:4n-6), the 
precursor of eicosanoids. The two biologically active n-3 PUFA are eicosapentaenoic 
acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3). In contrast, the 
biological effect of the third major marine n-3 PUFA, docosapentaenoic acid (DPA; 
22:5n-3), is virtually unknown. EPA and DHA are found in high concentrations in 
marine animals and fatty fish and are the primary sources of EPA and DHA for 
humans. n-3 PUFA are important elements of cell membranes and contributes to the 
function of various membrane channels and receptors (69). It is noteworthy that DHA 
is most abundant in the membranes of excitable cells such as retinal and cardiac cells, 
as well as in brain membrane lipids and synapses (70).  
 
 
Effect of marine n-3 PUFA on risk of cardiovascular 
disease 
 
Given the increased prevalence and incidence of CVD among patients with PsA, there 
is a need for more evidence on appropriate screening tools and preventive care to 
reduce the risk of CVD in these patients (71). A possible approach might be an 
increased intake of marine n-3 PUFA as beneficial effects on CVD have been 
suggested from several epidemiological studies, experimental data and clinical trials 
of these fatty acids (72).  
Danish researchers Bang and Dyerberg first reported that a seafood-based diet in the 
Inuit population of Greenland might reduce CVD (73,74). Ever since n-3 PUFA 
continue to attract interest as a possible lifestyle measures and medications for the 
prevention of CVD. 
The cardioprotective effect of n-3 PUFA might include antiatherosclerotic, 
antithrombotic, BP lowering, triglyceride lowering, effect on endothelial function, 
antiarrhythmic and modulation of autonomic activity (75–78). Furthermore, much 
interest has recently focused on anti-inflammatory effects of n-3 PUFA but most 
likely a combination of these mechanisms may explain the effect of marine n-3 PUFA 
on CVD (72). 
Several observational studies have found a positive association between n-3 PUFA 
and HRV (79–81) although data are not consistent (82). Thus, in a study of more than 
1.000 US adults, self-reported fish consumption, showed a positive correlation with 
HRV (83). A positive correlation between the content of n-3 PUFA in cell membranes 
and HRV have also been demonstrated (84,85) suggesting that incorporation of n-3 
PUFA in synaptic membranes could potentially influence the autonomic control of 
the heart. 
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n-3 PUFA is also known to have a mild antihypertensive effect (78,86). Additionally, 
some studies and a meta-analysis have investigated the effect of n-3 PUFA on arterial 
stiffness (87,88). The studies has typically used less than 4g/d of n-3 PUFA and have 
suggested improvement in PWV and arterial compliance in populations with 
hypertension, diabetes mellitus, dyslipidemia, metabolic syndrome and obesity. 
To date no studies have investigated the effect of n-3 PUFA on HRV or PWV in 
patients with PsA.  
 
 
 
n-3 PUFA, inflammatory processes and psoriatic 
arthritis  
 
Inflammation causes pain, tenderness and swelling of joints and entheses (89). 
Eicosanoids are key mediators and regulators of inflammation and include 
prostaglandins (PG), thromboxanes (TX), leukotrienes and other oxidative derivatives 
(90,91). The pathways for synthesizing the proinflammatory eicosanoids PGE2, TXA2 
and LTB4 and the side product, 5-hydroxyeicosatetraenoic acid (5-HETE) are well 
established, with AA being the only substrate for this synthesis derived from n-6 
PUFA.  
PGE2 has pro-inflammatory effects, including increasing vascular permeability, 
vasodilation, blood flow and local pyrexia and potentiation of pain caused by other 
agents. LTB4 increases vascular permeability, enhances local blood flow, is a potent 
chemotactic agent for leucocytes, induces release of lysosomal enzymes and enhances 
release of reactive oxygen species and inflammatory cytokines such as TNFα, IL-1b 
and IL-6 (91). The efficacy of non-steroidal anti-inflammatory drugs (NSAID), which 
act to inhibit synthesis of PGE2 and LTB4, indicates the importance of this pathway 
in the pathophysiology of the disease. In line with this, increased levels of AA and 
LTB4 have been demonstrated in psoriatic plaques (92) and PGE2 and LTB4 are found 
in the synovial fluid of patients with PsA (93).  
The marine n-3 PUFA, EPA and DHA compete with AA as a substrate for eicosanoid 
production. Increased consumption of these fatty acids results in their incorporation 
into cell membranes of leukocytes (94,95). Studies suggests that EPA and DHA is 
incorporated into cell membranes within days and may reach a steady state within two 
weeks of supplementation (96,97). The incorporation of EPA and DHA occurs in a 
dose-response manner (97–100). A previous study in healthy volunteers reported that 
EPA intake of 1.35g/d for 3 months was not sufficient to change PGE2 production in 
stimulated mononuclear cells, whereas EPA intake of 2.7 g/d was (98). When n-3 
PUFA, especially EPA is abundant, the synthesis of the proinflammatory PGE2 and 
LTB4 are suppressed and the less inflammatory PGH3 and LTB5 are increased 
(101,102). n-3 PUFA-derived mediators may even act as antagonists of the AA-
derived mediators (103). 
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Figure 1-5 Metabolism of n-6 PUFA and n-3 PUFA and formation of eicosanoids. 
PUFA: polyunsaturated fatty acids; EPA: eicosapentaenoic acid; COX: 
cyclooxygenase; LOX: lipoxygenase. 
 
Several controlled trials using n-3 PUFA have demonstrated a reduction in 
inflammation, joint pain and NSAID use in patients with RA (104–106). Similarly 
many authors have studied the role of n-3 PUFA in the prevention, treatment and 
maintenance of remission of inflammatory bowel disease (107–109). In contrast, only 
two small randomized and controlled studies have evaluated the role of n-3 PUFA in 
PsA (Table 1-4). These studies have shown changes in leukotriene and TX levels with 
n-3 PUFA supplementation, but no changes in the clinical outcomes (110,111). 
Therefore, investigating the effect of n-3 PUFA in patients with PsA seems to be of 
importance.  
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Table 1-4 Randomized controlled trials investigating clinical outcomes with daily 
intake of n-3 PUFA compared with placebo in patients with psoriatic arthritis. PsA: 
psoriatic arthritis; PUFA: polyunsaturated fatty acids; DHA: docosahexaenoic acid; 
EPA: eicosapentaenoic acid; NSAID: non-steroidal anti-inflammatory drug; VAS: 
Visual analouge scale for pain; PASI: psoriasis area and severity index CRP:C-
reactive protein; LTB4: leukotriene B4; TXA2: Thromboxane A2. 
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CHAPTER 2. HYPOTHESES AND AIMS  
The hypotheses of this thesis were: 
 
 Instruction and training in enthesitis score improve interobserver variation in 
enthesitis assessment. Furthermore, evaluation of enthesitis with US 
examination is correlated to clinical assessment of enthesitis 
 Marine n-3 PUFA improve disease activity, have analgesic-sparing effect, 
and anti-inflammatory effects measured by formation of leukotrienes from 
activated granulocytes in patients with PsA 
 Marine n-3 PUFA have a beneficial effect on cardiac autonomic and 
hemodynamic function evaluated by HRV and PWV in patients with PsA 
 
 
The aims of the thesis were to investigate the hypotheses by: 
 
 Examining if training in standardised assessment of enthesitis according to 
LEI and SPARCC improve interobserver variation in patients with 
established PsA. Furthermore, to compare US and clinical assessment of 
enthesitis for the detection of entheseal abnormalities in patients with PsA 
(Study I) 
 Study the effect of n-3 PUFA on outcome measures for disease activity and 
use of analgesics in patients with PsA. In addition, to investigate the effect 
of n-3 PUFA on inflammation, measured by leukotriene formation from 
stimulated granulocytes (Study II) 
 Investigating whether supplementation with a moderate to high (3 g) daily 
dose of marine n-3 PUFA for 24 weeks has a beneficial effect on cardiac 
autonomic function determined by HRV and arterial stiffness represented by 
BP, PWV and central BP in patients with PsA (Study III) 
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CHAPTER 3. PRESENTATION OF 
STUDIES 
Study I 
 
1.1. Study objectives  
 
The objective of this study was to determine the effect of training on clinical 
assessment of enthesitis and to compare US with clinical examination for the detection 
of entheseal abnormalities in patients with PsA. 
1.2. Study design, population and methods 
 
Outpatients with PsA according to Classification Criteria for PsA (CASPAR criteria) 
were enrolled from the Department of Rheumatology, Aalborg University Hospital, 
Aalborg, Denmark, during visits at the clinic. All participants gave their informed 
consent, and the regional ethics committee, The North Denmark Region, approved the 
study. The inclusion criteria were PsA in adults above 18 years of age with any disease 
activity while exclusion criteria were treatment with biological drugs, or treatment 
with oral/intramuscular corticosteroids during the past 3 months.  
 
Four patients and one healthy control were assessed for enthesitis with the SPARCC 
index and LEI by 20, before and after a formal group training session to validate the 
effect of training.  
 
In a different setting, 20 patients with PsA were examined with US (grey scale (GS) 
and power Doppler (PD)) and underwent clinical enthesitis examination with LEI, 
SPARCC, Psoriasis Area and Severity Index (PASI) and Disease Activity Score 
(DAS66/68-CRP). The US examination evaluated the following lesions at each site: 
1. Hypoechogenicity and increased thickness of the tendon insertion 
2. Enthesophytes 
3. Calcifications  
4. Erosions  
5. PD signal at enthesis. 
Plasma level of C-reactive protein (CRP) was measured with immunoturbidimetric 
method (Roche-Cobas 6000/8000, Rotkreuz, Switzerland). The assay range was 0.3–
350 mg/l (SD ±0.8 in values < 7).  
 
For more detailed description of methods and statistical analysis, see Appendix A 
(Manuscript I). 
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1.3. Results 
 
The study population had a mean age of 49 years, mean disease duration of 18.1 years, 
mean DAS66/68-CRP of 2.9, mean PASI of 3.1, 75% were treated with methotrexate 
and 50% used NSAID on a weekly basis.  
Comparing ICCs for LEI and SPARCC index before and after training showed 
significantly higher intraclass correlation coefficient (ICC) after training for both 
indices (Table 3-1). An increase in both SPARCC and LEI enthesitis scores was found 
after training. LEI and SPARCC index revealed only a moderate correlation with 
DAS66/68-CRP and there were no significant correlations between CRP levels and 
the two enthesitis scores.  
 
 Before 
instruction 
After instruction Comparing ICCs before 
and after instruction 
Results ICC (95% CI) ICC (95% CI) Bootstrap Z (p-values) 
LEI 0.18 (0.03 - 0.79) 0.82 (0.51 - 0.99) 2.85 (0.004) 
SPARCC 0.38 (0.12 - 0.90) 0.67 (0.35 - 0.97) 2.17 (0.03) 
 
Table 3-1 Mean score and Intraclass Correlation Coefficients for LEI and SPARCC Enthesitis 
Index before and after instruction. LEI: Leeds Enthesitis Index; SPARCC: Spondyloarthritis 
Research Consortium of Canada; ICC: Intraclass Correlation Coefficient; CI: Confidence 
interval 
 
 
Looking at the different US parameters, there were highly significant correlation 
between hypoechogenicity and tendon thickness and clinical scores. There were no 
correlations between PD and clinical scores. Findings of more chronical lesions such 
as enthesophytes and erosions were not correlated with clinical scores.  
 
1.4. Methodological considerations 
 
Study I was based on two prospective studies with 20 participants. The low number 
of patients included was clearly a limitation of the study.  
In the training session, only five patients were clinically assessed for enthesitis, 
although 20 rheumatologists performed the assessments repeatedly. The small study 
population may influence the generalization to the PsA population, but given the 
demographic characteristics in this group, compared with previous studies 
(45,112,113) it would be reasonable to consider the included patients representative 
of patients with PsA in general.  
The reproducibility of US findings is important to consider as this is a potential 
weakness of US. The intra and inter-reader variation has been studied and there has 
been an attempt to minimise these variations by training and reaching a consensus on 
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scoring of pathology (114–116). In this study, US intrareader reliability was assessed 
in static images by Quadratic-weighted kappa and showed moderately repeatable grey 
scale scores (kappa 0.71) and highly repeatable PD scores (kappa 0.89).  
US was performed with the joints and entheses not fully relaxed; this may contribute 
to a reduction of the sensitivity of PD (141–144). Studies by Gutierrez et al. (145), 
Koenig et al. (146) and Zappia et al. (147) have revealed changes in intratendinous 
PD related to joint position. The position of the joints for the evaluation of PD at the 
enthesis is an important limitation of this study. Examination positions for US should 
be studied to evaluate the optimal position for PD.  
The US examination was not performed in a control group, and some of the structural 
abnormalities may be due to degenerative changes developed with age. However, the 
study group was relatively young. Furthermore, the size of the population might have 
weakened the correlation analyses, and does not allow an accurate evaluation of the 
US examination.  
 
 
1.5. Conclusion 
 
In conclusion, there was a substantial effect of training on the reliability among 
rheumatologists in the assessment of enthesitis in patients with PsA. In addition, US 
may be more sensitive for the evaluation of bone changes, but further longitudinal 
studies are needed to determine if these findings correlate with disease activity and 
response to treatment. Since LEI is less time-consuming than SPARCC index, it might 
be more feasible to use in daily practice. 
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Study II 
 
1.1. Study objectives  
 
Study II aimed to investigate the effect of marine n-3 PUFA on outcome measures for 
disease activity, use of analgesics, and inflammation measured by leukotriene 
formation from stimulated granulocytes in patients with PsA. 
1.2. Study design, population and methods  
 
The study was designed as a randomized, double blind, placebo-controlled trial. For 
24 weeks, patients received a daily intake of 6 identical looking capsules containing 
either 3 g of n-3 PUFA (50% EPA and 50% DHA) or 3 g of olive oil (containing 
approximately 80% of oleic acid and 20% linoleic acid). All participants gave their 
written informed consent and the regional ethics committee of The North Denmark 
Region approved the study (reference number N20120076). Good Clinical Practice 
(GCP) inspectors monitored the study and the GCP ethical and scientific quality 
requirements were followed.  
The inclusion criteria were PsA defined by CASPAR criteria in adults above 18 years 
of age with any disease activity. Exclusion criteria were pregnancy, treatment with 
biological drugs, or with oral corticosteroids.  
Compliance was assessed by counting capsules during the last visit. Patients were 
defined as non-compliant if missing >15% of capsules, and these patients were not 
included in the per-protocol analysis.  
At baseline, information on duration of PsA, medical history, smoking habits and diets 
was obtained by medical interview. A trained investigator performed the clinical 
evaluation at baseline and study end to minimize interobserver variation according to 
the findings in Study I. Information about the type and dosage of NSAID and 
paracetamol intake was collected by interview at baseline and at study end. NSAID 
and paracetamol use was quantified in number of tablets taken per week (113). 
Blood samples were obtained at baseline and study end for assessment of fatty acid 
composition of granulocytes, analysis of leukotriene formation from stimulated 
granulocytes, and routine laboratory evaluation including plasma levels of CRP. 
Plasma level of CRP was measured with immuntubidimetric method. The assay range 
was 0.3 – 350 mg/l (SD ±0.8 in values < 10). 
For more detailed description of methods and statistical analysis, see Appendix B 
(Manuscript II). 
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1.3.  Results 
 
Figure 3-1 shows the study flow diagram. Only intention to treat analysis is presented. 
Per-protocol analysis did not change the results. 
 
 
 
Figure 3-1 Flow diagram of the study participants  
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n=145
Control
n=72
n=1 excluded 
because of atrial
fibrillation 
n=1 excluded after 
initiation of 
biological 
treatment 
n=3 dropped out 
for personal 
reasons 
n=2 dropped out 
because of side 
effect
Completed 
study
n=65
Eligible for 
leukotriene 
measurements 
n=63
n-3 PUFA
n=73
Completed 
study
n=68
Eligible for 
leukotriene 
measurements
n=67
n=1 excluded 
because of atrial
fibrillation 
n=1 excluded 
because of 
pregnancy
n=3 dropped out 
for personal 
reason 
n=1 did not fulfil 
CASPAR criteria 
for PsA
n=2 underwent 
biologic therapy
n=3 received oral 
corticosteroids 
n=2 planned 
pregnancy  
n=66 declined to 
participate
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 n-3 PUFA  
(n = 63) 
 Control 
(n = 67) 
  
 Baseline Week 24 Difference 
(CI) 
Baseline Week 24 Difference 
(CI) 
P 
VAS 29.73 30.12 0.39  
(-3.46 ; 4.23) 
36.69 34.45 -2.24  
(-6.40 ; 1.93) 
0.36 
HAQ 0.69 0.70 0.00  
(-0.07 ; 0.08) 
0.76 0.78 0.02  
(-0.06 ; 0.09) 
0.81 
DAS66/68-
CRP 
2.56 2.34 -0.22  
(-0.38 ; -0.05) 
2.76 2.71 -0.05  
(-0.25 ; 0.15) 
0.20 
Tender joint 
count 
5.10 2.67 -2.43  
(-4.53 ; -0.34) 
4.16 4.10 -0.06  
(-1.70 ; 1.58) 
0.08 
Swollen joint 
count 
0.61 0.30 -0.31  
(-0.68 ; 0.05) 
0.87 0.84 -0.03  
(-0.61 ; 0.55) 
0.41 
ASDAS 2.02 1.95 -0.07  
(-0.23 ; 0.10) 
2.33 2.26 -0.07  
(-0.24 ; 0.10) 
0.96 
BASDAI 10.68 11.29 0.62  
(-3.25 ; 4.48) 
15.83 14.37 -1.46  
(-4.76 ; 1.84) 
0.42 
BASMI 1.36 1.36 0.00  
(-2.24 ; 2.24) 
1.21 1.52 0.30  
(-0.99 ; 1.59) 
0.82 
LEI 2.56 2.34 -0.44  
(-0.83 ; -0.05) 
2.76 2.71 -0.42  
(-0.80 ; -0.04) 
0.94 
SPARCC 2.52 1.85 -0.67  
(-1.32 ; -0.01) 
2.54 1.94 -0.60  
(-1.36 ; 0.16) 
0.89 
PASI 2.23 1.61 -0.62  
(-1.09 ; -0.14) 
2.36 2.04 -0.31  
(-0.98 ; 0.35) 
0.47 
NSAID  
no. of 
tablets/week 
3.88 1.64 -2.45  
(-3.27 ; -1.62) 
4.17 2.91 -1.39  
(-2.02 ; -0.75) 
0.04 
Paracetamol 
no. of 
tablets/week 
4.32 1.93 -2.63  
(-3.52 ; -1.73) 
4.38 3.07 -1.36  
(-2.18 ; -0.53) 
0.04 
 
Table 3-2 Clinical outcomes presented as means with 95% confidence intervals at baseline and 
after 24 weeks of supplement for both groups.CI: Confidence Interval; P: P for difference 
between the two groups of supplement; VAS: Visual analogue scale for pain; HAQ: health 
assessment questionnaire; DAS66/68-CRP: 66/68 joint count disease activity score based on 
CRP; ASDAS: ankylosing spondylitis disease activity score; BASDAI: Bath ankylosing 
spondylitis disease activity index; BASMI: Bath ankylosing spondylitis metrology index; LEI: 
Leeds enthesitis index; SPARCC: Spondyloarthritis research consortium of Canada enthesitis 
index; PASI: psoriasis area and severity index; NSAID: nonsteroidal anti-inflammatory drugs. 
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Clinical outcomes 
Supplementation with n-3 PUFA for 24 weeks led to significant reductions in 
DAS66/68-CRP, tender joint count, LEI, SPARCC, and PASI within the group, but 
these changes were not significantly different between groups (Table 3-2). The n-3 
PUFA group also showed a significant decrease in NSAID and paracetamol use. Even 
though there was a small decrease in NSAID and paracetamol use in the control group, 
the reduction in the n-3 PUFA group was significantly larger compared with controls 
(p = 0.04) (Table 3-2).  
Leukotrienes and CRP 
After 24 weeks, there was a decrease in LTB4 formation and an increase in LTB5 
formation in stimulated granulocytes in the n-3 PUFA group, whereas there were no 
significant changes in the control group. Compared with the control group the n-3 
PUFA group showed a significantly lower formation of LTB4 (p = 0.004) and a 
significantly higher formation of LTB5 (p < 0.001) (Figure 3-2 and 3-3).  
There were no significant changes in CRP from baseline to study end within or 
between groups.  
The formation of LTB4 or LTB5 from stimulated granulocytes was not associated with 
outcome measures for disease activity at baseline or after intervention.  
 
 
 
 
Figure 3-2 Formation of leukotriene B4 from stimulated granulocytes presented as 
mean median ng/107 granulocytes with 95% confidence intervals at baseline and after 
24 weeks of supplementation for each group.  
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Figure 3-3 Formation of leukotriene B5 from stimulated granulocytes presented as 
means with 95% confidence intervals at baseline and after 24 weeks of 
supplementation for each group. 
 
1.4. Methodological considerations 
 
Study II is by far the largest study examining the clinical effect of n-3 PUFA in 
patients with PsA, although no power calculation was performed. 
Olive oil was used as control because olive oil had no anti-arrhythmic effect in 
previous studies (117,118). However, olive oil may itself have anti-inflammatory 
actions (119) because it contains phenols, such as tyrosol and b-sitosterol (120). 
Therefore, it is not the ideal placebo oil as it is not inert regarding inflammation. The 
anti-inflammatory effects of olive oil might explain the improvements in DAS, tender 
joint count, LEI, SPARCC, and PASI in the control group (Table 3-2) and thus the 
lack of a significant difference between the groups. However, the mean intake of 
monounsaturated fat in Denmark is 36 g/d, primarily as oleic acid (121), and therefore, 
adding 3 g/d of olive oil would not be expected to have a substantial effect on the 
results. In line with this, we found no significant changes in the content in 
granulocytes of oleic acid and linoleic acid (main components of olive oil) in the 
control group (Appendix B, Manuscript II).  
The reduction in the use of NSAID and paracetamol in the n-3 group may also have 
diminished the effect of n-3 PUFA on outcome measures for disease activity 
Moreover, approximately 75% of the participants were treated with DMARDs and 
had a low disease activity at baseline (Table 3-2), making it more difficult to show an 
effect of any intervention. Furthermore, the results might be different in newly 
diagnosed patients and in patients with high disease activity. 
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In this study, CRP did not change after supplementation. Measuring high-sensitivity 
CRP might have altered the results. However, the method used in the study assessed 
levels of CRP as low as 0.3 mg/l.  
The formation of leukotrienes from stimulated granulocytes may have a significant 
intraindividuel variability, which requests further exploration. Moreover, 
the formation of leukotrienes is determined after stimulation and may vary from the 
values during (patho)physiological conditions. 
Finally, two hundred and nineteen patients were assessed for eligibility, but 66 
patients declined to participate through choice and this may have introduced selection 
bias to the study.  
The main strength of the study is the double blind, randomized, and prospective design 
comparing subjects with clinically relevant phenotype in a reasonable sized study. 
Trained investigators evaluated clinical outcomes for disease activity and the same 
investigator performed clinical assessments at baseline and study end to minimize 
interobserver variation, as outlined in Study I. Furthermore, only 12 participants were 
lost to follow-up and 133 completed the study. 
 
1.5. Conclusion  
 
This study suggests that use of n-3 PUFA supplementation at dosages of 3g/d for 6 
month may be effective at reducing NSAID and paracetamol use in patients with PsA. 
There was no significant improvement in outcome measures for disease activity 
compared with the control group. However, the reduction in analgesic use might 
partly explain this and furthermore, it indicates a beneficial effect on joint 
inflammation and pain. These findings were supported by the reduction in LTB4 
formation after 24 weeks of supplementation with n-3 PUFA.  
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Study III 
 
1.1. Study objectives  
 
This study aimed to examine the effect of daily supplementation with 3g marine n-3 
PUFA for 24 weeks on cardiac autonomic and hemodynamic function represented by 
BP, HR, HRV, PWV and central BP in patients with PsA. 
 
1.2. Study design, population and methods  
 
Study design and population are described in Study II. Additionally, a food 
questionnaire was used to assess the patients’ fish consumption (see Appendix C, 
Manuscript III). At both visits conventional cardiovascular risk factors such as 
smoking habits, BP, body mass index (BMI) and waist to hip ratio were assessed.  
Five min. HRV recordings were obtained with SphygmoCor Technology in each 
patient. HRV was recorded according to current recommendations (122). HRV were 
analysed in the time-domain and the following variables were obtained: 
 HR: Heart rate 
 RR: mean of all normal RR intervals during the 5 min recording 
 SDNN: standard deviation of all normal RR intervals in the 5 min. recording 
 pNN50: percentage of successive RR-interval differences > 50 ms 
 RMSSD: square root of the mean of the sum of the squares of differences 
between adjacent intervals 
 
 
 
Figure 3-4 Heart rate variability with R to R intervals 
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PWV, pulse wave analysis and central BP measurements were performed non-
invasively with the Sphygmocor system (AtCor Medical, Sydney, NSW, Australia), 
as described previously (58) and according to international recommendations (123).  
 
 
 
 
Figure 3-5 Pulse wave velocity calculation; carotid-femoral measurements showing 
the pressure waveform following an impulse at site A carotid artery and site B femoral 
artery. 
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1.3. Results 
 
See Figure 3-1 for study flow diagram.  
At baseline patients with the highest fish intake had a significantly higher RR than 
patients with the lowest intake (p = 0.03). In addition, patients in the tertile with the 
highest content of DHA in granulocytes had the highest RR (p = 0.04) whereas the 
content of EPA in granulocytes was not associated with RR. The associations between 
dietary fish intake and RR seemed to be dose dependent (Figures 3-6 and 3-7).  
 
 
 
 
 
Figure 3-6 The relation between baseline RR (ms) and fish intake presented in tertiles 
with confidence interval. RR: Mean of all normal RR-intervals in HRV recording; *: 
Significant difference in RR between the lower and the upper tertile, p = 0.03. 
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Figure 3-7 The relation between baseline RR (ms) and content of DHA in granulocytes 
presented in tertiles with confidence interval. HRV: Heart Rate Variability; RR: Mean 
of all normal RR-intervals in HRV recording; DHA: docosahexaenoic acid; *: 
Significant difference in RR between the lower and the upper tertile, p = 0.04. 
 
Intention to treat analysis  
 
Supplementation for 24 weeks revealed a trend towards an increase in RR (p = 0.06) 
and a decrease in HR (p = 0.12) comparing the n-3 PUFA group with the control group 
(Table 3-3). There were no significant changes in BP, PWV or central BP in the n-3 
PUFA supplemented group or between the n-3 PUFA and control group.  
 
Per-protocol analysis  
 
A significant increase in RR and decrease in HR within the n-3 PUFA group was 
found after 24 weeks and these data was substantiated by a significant difference in 
changes in RR (p = 0.03) and HR (0.02) between the n-3 PUFA and control group 
(Table 3-4). However, there were no significant changes in BP, PWV or central BP 
within the n-3 PUFA group or between the groups. Adjustment for age, sex, smoking, 
diabetes mellitus, hypertension, BP, hypercholesterolemia, NSAID treatment and 
DAS66/68 did not affect the results.   
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n-3 PUFA  
(N = 68) 
Control  
(N = 60) 
 
 Baseline Week 24 Difference 
(CI) 
Baseline Week 24 Difference 
(CI) 
P 
HR, min-1 63.83 63.29 -0.61 
 (-1.92 ; 0.70) 
63.39 64.38 0.96  
(-0.55 ; 2.47) 
0.12 
RR, ms 956.55 969.94 13.38  
(-5.06; 31.83) 
964.02 950.53 -13.48  
(-35 ; - 8.69) 
0.06 
PNN50 % 10.68 11.29 0.62  
(-3.25 ; 4.48) 
15.83 14.37 -1.46  
(-4.76 ; 1.84) 
0.42 
SDNN ms 49.37 48.12 -1.24  
(-8.46 ; 5.97) 
49.71 47.41 -2.30  
(-6.79 ; 2.20) 
0.81 
RMSSD ms 36.59 37.58 0.99  
(-7.13 ; 9.12) 
39.84 39.15 -0.69  
(-6.23 ; 4.85) 
0.73 
Systolic BP 
mmHg 
138.20 134.53 -3.67  
(-6.69; -0.65) 
134.41 133.18 -1.23  
(-4.59 ; 2.14) 
0.28 
Diastolic BP 
mmHg 
82.61 81.82 -0.79  
(-2.35 ; 0.77) 
82.36 80.92 -1.44 
(-3.26 ; 0.39) 
0.59 
PWV m/s 7.80 7.81 0.01  
(-0.44 ; 0.46) 
7.40 7.48 0.08  
(-0.33 ; 0.49) 
0.82 
Central 
systolic BP 
mmHg 
114.82 112.24 -2.58  
(-4.84; -0.32) 
113.29 111.38 -1.91 
(-4.77 ; 0.95) 
0.71 
Central 
diastolic BP  
mmHg 
96.04 93.76 -2.28  
(-4.10; -0.47) 
95.45 94.17 -1.29  
(-3.51 ; 0.94) 
0.49 
PWA AIx  26.42 27.54 1.12  
(-0.56 ; 2.80) 
26.97 25.82 -1.15  
(-2.78 ; 0.47) 
0.05 
  
Table 3-3 Intention to treat data with no adjustments. Outcomes presented as means with 
95% confidence intervals at baseline and after 24 weeks of supplement for both groups. 
CI: Confidence Interval; P = P for difference between the two groups of supplement; HR: 
Heart rate; HRV: Heart rate variability; PWV: Pulse wave velocity; BP: blood pressure; AIx: 
central Augmentation Index 
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 n-3 PUFA 
(n=58) 
  Control 
 (n=56) 
   
 Baseline Week 
24 
Difference 
(CI) 
Baseline Week 
24 
Difference 
(CI) 
P  
HR 63.24 61.73 -1.51  
(-2.89 ; -0.13) 
63.39 64.38 0.98  
(-0.54 ; 2.50) 
0.02 
RR ms 964.14 990.39 26.25  
(6.21 ; 46.30) 
964.02 950.53 -13.48  
(-35.66 ; 8.69) 
0.01 
PNN50 % 11.39 11.65 0.26  
(-4.06 ; 4.58) 
15.83 14.37 -1.46  
(-4.76 ; 1.84) 
0.52 
SDNN ms 51.56 49.36 -2.20  
(-9.96 ; 5.56) 
49.71 47.41 -2.30 ( 
-6.79 ; 2.20) 
0.98 
RMSSD ms 39.10 37.85 -1.25  
(-9.41 ; 6.91) 
39.84 39.15 -0.69  
(-6.23 ; 4.85) 
0.91 
BP Systolic 
mmHg 
137.67 134.29 -3.38  
(-7.03 ; 0.26) 
134.41 133.18 -1.23  
(-4.59 ; 2.14) 
0.39 
BP Diastolic 
mmHg 
81.96 80.88 -1.08  
(-2.89 ; 0.74) 
82.36 80.92 -1.44  
(-3.26 ; 0.39) 
0.78 
PWV m/s 7.66 7.61 -0.04  
(-0.51;- 0.43) 
7.40 7.48 0.08  
(-0.33 ; 0.49) 
0.70 
Central BP 
systolic 
mmHg 
114.62 112.17 -2.44  
(-5.17 ; 0.28) 
113.29 111.38 -1.91  
(-4.77 ; 0.95) 
0.79 
Central BP 
diastolic 
mmHg 
95.50 93.13 -2.37  
(-4.49 ; -0.24) 
95.45 94.17 -1.29  
(-3.51 ; 0.94) 
0.49 
PWA Aix 26.42 27.51 1.12  
(-0.56 ; 2.80) 
27.02 25.84 -1.15  
(-2.78 ; 0.47) 
0.06 
 
Table 3-4 Per-protocol data with no adjustments. Outcomes presented as means with 95% 
confidence intervals at baseline and after 24 weeks of supplement for both groups.  
HR: Heart rate; CI: Confidence Interval; P = P for difference between the two groups of 
supplement; PWV: Pulse wave velocity; BP: blood pressure; AIx: central Augmentation Index 
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1.4. Methodological considerations 
 
In Study III the power calculation was based on previous literature on HRV (51,124) 
and to achieve α = 0.05 and 1-β = 0.80 a sample size of 63 subjects in each group was 
needed. A total of 145 patients were included and 133 completed, fulfilling the power 
calculation. 
All analyses were performed both as intention to treat and per-protocol (patients who 
completed the entire clinical trial according to the protocol and consumed > 85% of 
the assigned supplement) analyses. Intention-to-treat analysis provide unbiased 
comparisons among the treatment groups because it avoids the bias associated with a 
non-random loss of the participants. On the other hand it may also be reasonable to 
compare results from those who actually followed the intervention with results in 
controls (per-protocol analysis). The difference in HRV in the intention to treat and 
per-protocol analyses might be explained by non-compliance.  
Five minutes HRV recordings were used to assess cardiac autonomic function. This 
method may limit the measurement of vagal predominance during night-time. 
However, other studies assessing patients with PsA have obtained 5 minutes HRV 
with results comparable to our findings. 
Brachial BP was measured according to international recommendation. Ambulatory 
BP monitoring, with its ability to gather multiple readings both during the normal 
activities of the day and the night, might have been a more veritable measure of BP 
(125). However, central hemodynamic parameters were obtained. Clinical trials have 
shown that the monitoring of peripheral BP is not sufficient to describe the actual 
response to drug treatment, and central hemodynamic parameters should be taken in 
account; and that the assessment of central BP, together with aortic stiffness and 
pressure wave reflections, may give new perspectives in CVD risk assessment (126–
128). 
For further methodological considerations, see Study II. 
 
 
1.5. Conclusion  
 
In conclusion, Study III demonstrated a beneficial effect of n-3 PUFA on RR and HR 
in patients with PsA in baseline and per-protocol analysis. However, there were no 
changes observed in PWV and central BP parameters after intervention. The results 
may indicate a beneficial effect of n-3 PUFA on cardiac autonomic tone in patients 
with PsA and further large-scale studies are needed to demonstrate whether this 
translates into a reduction of CVD in these patients. 
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CHAPTER 4. GENERAL DISCUSSION  
Approximately 35% of the patients with PsA present with enthesitis at the time the 
diagnose is established (129). Enthesitis represents PsA-specific pathophysiological 
manifestations that distinguish it from other forms of inflammatory arthritis and 
should be included in regular PsA assessments to facilitate better understanding of 
disease risk factors, prognosis and development of targeted treatments. However, 
assessment of enthesitis would have to be reconciled with feasibility/simplicity. To 
date the use of clinical and US outcome measures for enthesitis has been limited 
possibly by time restraints, lack of training and lack of consensus on the use of these 
tools (130,131).  
ICC for both LEI and SPARCC increased significantly after training in Study I. It may 
be of importance that the ICCs obtained before the training session were very low and 
indicate the need for training in standardised enthesitis counts before using such 
indices in clinical practice. In addition, both LEI and SPARCC enthesitis scores 
increased significantly after training, which might reflect an increased ability to detect 
enthesitis burden.  
The effect of training on the reliability of joint count has previously been investigated 
and resulted in a reduction in the interobserver variation (132). The results from Study 
I indicates the need for training in enthesitis scores in patients with PsA in the daily 
clinical settings. The training exercise was brief and informal, yet it was followed by 
a significant reduction in the interobserver variation.  
Both enthesitis scores were only moderately associated with DAS66/68-CRP and 
there were no correlation with CRP. As outpointed in previous studies DAS will likely 
underestimate the burden of disease in PsA and its multiple domains should be 
assessed (133,134). In a previous study of ankylosing spondylitis, enthesitis was only 
correlated to high sensitive CRP and not routine CRP test (135), indicating minimal 
influence of enthesitis on CRP. Overall, CRP may be a more important marker of 
disease activity in RA (136) than in PsA (137). 
US findings in enthesitis are often split into features of soft-tissue inflammation 
(hypoechogenicity, tendon thickness and PD) and features of tissue damage (bone 
changes) to reflect the reversible and irreversible pathological components of 
enthesitis. Similar to a previous study (138), US results from Study I, suggest that 
enthesophytes and erosions are more chronic lesions, asymptomatic and not detectable 
with clinical examination. However, in a recent study of the OMERACT US Task 
Force agreement was not reached on a definition of how to separate acute 
inflammation from chronic bone changes (116). Furthermore, a previous study have 
shown that calcifications and enthesophytes found by US might be a common 
pathology in trauma and degenerative changes in the general population (139).  
The lack of PD finding at sites with clinical enthesitis might be explained by the fact 
that there are fewer vessels in inflamed enthesis compared with synovium making it 
more difficult to visualize (139,140). Furthermore, US was performed with the joints 
positioned as previously described (28) but not fully relaxed; this may also contribute 
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to reduction of the sensitivity of PD (141–144). Examination positions for US should 
be studied to evaluate the optimal position for PD.  
Overall, further longitudinal studies in larger PsA populations are needed to decide 
how to interpret and use US findings and to determine the value of training. However, 
the improvement in interobserver variation and the increased ability to detect 
enthesitis burden after training session, led to training in enthesitis assessment before 
evaluation of clinical outcomes in Study II. 
 
With 145 participants and only 12 participants not completing, Study II and III are the 
largest investigations on the effect of marine n-3 PUFA on cardiovascular function 
and inflammation in patients with PsA. 
In Study II, there was a significant decrease in DAS66/68-CRP, LEI, SPARCC, and 
PASI within the n-3 PUFA group although not significantly compared with controls. 
However, the participants supplemented with n-3 PUFA significantly reduced the use 
of NSAID and paracetamol, which might have masked a clinical effect of marine n-3 
PUFA. In line with this, n-3 PUFA also induced less formation of proinflammatory 
LTB4 from stimulated granulocytes. 
Previous studies in patients with inflammatory joint diseases have focused on the use 
of n-3 PUFA in RA (105,140–142) and only two small randomized controlled studies 
and one non-controlled study have examined the effect of n-3 PUFA on clinical 
outcomes in patients with PsA. Veale et al. (111) thus studied the effect of a very 
small dose of daily n-3 PUFA supplements (240 mg EPA and 132 mg DHA) or 
placebo in 38 PsA patients for 12 months. They found no differences in clinical 
outcomes, NSAID use, or CRP levels. However, n-3 PUFA significantly decreased 
LTB4 formation from granulocytes. It is plausible that the dose used was too low to 
have a clinical effect although there was a reduction in LTB4 formation. Another 
randomised and controlled study by Madland et al. (110) used seal oil as the source 
of n-3 PUFA (6.1 g/day) for 2 weeks in 40 patients, 20 in each group. The authors did 
not find any significant changes in joint pain. These data might be explained by the 
short intervention period as a symptomatic effect of n-3 PUFA has previously been 
shown to lack the immediacy of the NSAID with a latency of 6 to 12 weeks before 
symptomatic improvement (104,140). Finally, Lassus et al. conducted an un-
controlled study with 80 patients with psoriasis, 34 of whom had PsA. The participants 
were supplemented with 1.9 g n-3 PUFA/day in 8 weeks and the authors found a 
beneficial effect on skin symptoms and a decrease in joint pain.  
It remains to be determined how n-3 PUFA reduce pain, but it has been suggested that 
linoleic acid and AA promote nociception (143), whereas mediators derived from 
EPA and DHA promote anti-nociception (144). EPA/DHA may reduce pain due to 
suppression of inflammation (91) or direct effect on nerve tissue (145). In Study II, 
the use of analgesics and joint pain were reduced supporting an anti-nociceptive effect 
of n-3 PUFA.  
In addition, the reduction in NSAID use may reduce the known adverse effect of 
NSAID with potential risk of CVD. Data from Study III and previous studies also 
indicate that n-3 PUFA reduce the risk of cardiovascular events, including sudden 
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cardiac death (72,79), which may also be of relevance in patients with PsA because 
of their increased risk of CVD (11,12).  
Trials using oral, intravenous, and topical preparations of n-3 PUFA in patients with 
psoriasis have also investigated the effect on skin inflammation, and although the 
populations studied, and the outcomes assessed were heterogeneous, overall there is 
some evidence for a beneficial effect of n-3 PUFA in patients with psoriasis (146–
148). In a more recent open investigation of 30 patients with PsA Balbás et al. used 
PASI as outcome measure. The authors showed that patients with plaque psoriasis 
supplemented with 2.8 g EPA and 0.4mg DHA, significantly improved (p<0.0001) in 
the PASI score in the n-3 PUFA group compared with control after 8 weeks (147). In 
Study II, the n-3 PUFA group achieved a significant improvement in PASI within the 
group but the results were not significant compared with the controls. However, 
baseline mean PASI score was 2.3 indicating a low degree of skin inflammation in the 
study population and this might have affected the results.  
There are several reports of a decreased production of inflammatory eicosanoids from 
immune cells following a period of n-3 PUFA supplementation in healthy volunteers 
and patients with RA (119,149–152). Study II showed significant changes in LTB4 
and LTB5 formation and outcomes for disease activity in the n-3 PUFA supplemented 
group. This is consistent with findings of the previous studies of patients with RA. 
While the changes in LTB4 and LTB5 formation indicate an anti-inflammatory action 
of n-3 PUFA, it is unknown whether the induced changes in formation of 5-HETE 
and 5-HEPE is of clinical relevance. However, 5-HETE enhances lymphocyte 
proliferation, whereas 5-HEPE only has one-tenth the potency of 5-HETE in this 
respect (153).  
In Study II, results revealed no association between LTB4 formation from stimulated 
granulocytes and clinical outcomes and this could question the relevance of 
leukotrienes in PsA. However, it should be kept in mind that there may be a significant 
intraindividual variability in formation of leukotrienes and furthermore maximal 
capacity is determined after stimulation and not more (patho-)physiological 
conditions. The study population had a low mean disease activity at baseline and at 
study end, which also may have influenced this association. 
 
Previous studies of patients with RA have also reported an inverse correlation between 
n-3 PUFA use and inflammatory biomarkers such as CRP and erythrocyte 
sedimentation rate (154,155), although, these findings are not consistent (119,156–
159). However, PsA is long known to be distinct from RA in aspect of inflammatory 
biomarkers (137).  
In Study III, supplementation with 3 g n-3 PUFA daily for 24 weeks suggested 
beneficial effect on autonomic control of the heart in patients with PsA by increasing 
short-term HRV.  
At baseline, there was a significantly higher RR in the patients with the highest fish 
intake and content of DHA in granulocytes. These results suggest a beneficial effect 
of dietary fish consumption on cardiac autonomic control in patients with PsA. In the 
intention to treat analysis there was a trend towards increased RR and thereby a 
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reciprocal lowering of HR. The per-protocol analysis revealed a significant increase 
in RR and a decrease in HR in the n-3 PUFA group.  
HRV is considered a useful and reliable measurement of cardiac autonomic tone 
(160). An attenuated HRV indicates an increased cardiovascular risk in the general 
population (37) and in patients with CVD (161). Evidence also suggests that n-3 
PUFA improves HRV (77).The positive association between fish intake and RR at 
baseline and the increase in RR after intervention with n-3 PUFA found in this study 
is in line with previous studies of other high-risk patients and healthy subjects (79). 
The effect of n-3 PUFA on HR is also consistent with previous data showing that n-3 
PUFA reduces resting HR (80,162), an important risk marker for CVD (163).  
As a surrogate marker for cardiac autonomic tone, HRV reflects changes mediated by 
n-3 PUFA at the level of cardiac efferent stimuli (81,164). Interestingly, in Study III, 
baseline content of DHA but not EPA in granulocytes was positively associated with 
RR, which is consistent with previous findings (165,166). DHA is the most abundant 
n-3 PUFA in the brain and nervous system membrane lipids (167) and therefore might 
be most important for cardiac autonomic function. 
Central nervous system interplay with the viscera within the autonomic nervous 
system and the vagal nerve has multiple key roles in the homeostatic regulations of 
visceral functions. Recent studies have suggested anti-inflammatory role of the vagal 
nerve (42,43). This vagal function is thought to be mediated through several pathways, 
some of them debateable (29,168–170).  
A few studies have investigated HRV in PsA and demonstrated attenuated HRV. In a 
study with 38 patients with PsA and 25 healthy controls using 5-min HRV Gaydukova 
et al. (48) found that SDNN and pNN50 was significantly lower in patients with PsA 
compared with controls. Similarly, Proietti et al. (49) also used short-term HRV and 
found a significant difference in RMSDD between patients with psoriasis and 
controls. Compared with data from these previous studies baseline results from Study 
III supported an attenuated SDNN, pNN50 and RMSSD in patients with PsA.  
In a small study with 20 patients with PsA, Syngle et al. observed improvement in 
autonomic function after treatment with synthetic DMARDs during 12 weeks of 
treatment (51). Yet, no treatment strategy for cardiac autonomic dysfunction in PsA 
has been implemented. Thus, the possible beneficial effect of n-3 PUFA found in 
Study III may be of importance in the approach towards an improved cardiac 
autonomic function in PsA. 
 
n-3 PUFA is believed to have a mildly antihypertensive effect (86). Furthermore, 
studies and a meta-analysis of randomized and controlled human clinical trials 
examining the effect of n-3 PUFA on arterial stiffness has shown a reduction in arterial 
stiffness after treatment with less than 4g/d of n-3 PUFA in populations with 
hypertension, diabetes mellitus, dyslipidemia, metabolic syndrome and obesity 
(87,88). 
In Study III, no changes in BP, PWV, central BP and AIx measurements were 
observed. However, in most of the previous studies arterial stiffness was not assessed 
with carotid-femoral PWV (regarded as “golden standard”) as in this study. 
Furthermore, patients in Study III had a low disease activity score of 2.6 (sd = 0.9) at 
baseline and 75% of the patients received DMARDs. Thus, the investigated patient 
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group were in remission and results may not apply to patients with a more severely 
disease activity. In other chronic inflammatory diseases, such as RA and systemic 
vasculitis, PWV and AIx were increased compared with controls, but only in patients 
with active disease (60,171). Also, a higher dose of n-3 PUFA might have a more 
pronounced effect, but still we used a relatively high dose of n-3 PUFA in this study 
and higher doses are unlikely to be feasible on a long term basis.  
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CHAPTER 5. CONCLUSION AND 
FUTURE PERSPECTIVES  
The heterogeneity of clinical manifestations (e.g., oligoarthritis, polyarthritis, 
spondyloarthritis and ligamentous and tendon involvement) complicates assessment 
of PsA outcomes and broadens its impact on daily life. PsA has been shown to 
negatively affect health-related quality of life independently of psoriasis skin 
manifestations. Even with current medical therapies, many patients with PsA have 
persistent disease activity, and frequently ask whether dietary changes could improve 
their symptoms. Additionally, the critical impact of comorbidities such as CVD 
warrants focus and agreement on a comprehensive treatment strategy. 
 
The studies of this thesis have contributed to the evaluation of enthesitis assessment 
and the effect of n-3 PUFA on inflammation and risk of CVD in PsA.  
 
The study of enthesitis assessment showed that a two-hour training session in a 
standardized examination technique could potentially minimize interobserver 
variation in both LEI and SPARCC. Subsequently, the investigators of Study II were 
trained in enthesitis score and the same investigator assessed clinical outcomes at 
baseline and study end to reduce the interobserver variability.  
As hypothesized, Study II demonstrated that n-3 PUFA reduce the use of NSAID and 
paracetamol in patients with PsA. Although, no improvement in outcome measures 
for disease activity was found. However, the reduction in NSAID and paracetamol 
use may have influenced the clinical outcomes. LTB4 formations from stimulated 
granulocytes were significantly reduced after supplementation with n-3 PUFA, 
suggesting an anti-inflammatory effect in patients with PsA. Furthermore, n-3 PUFA 
improved mean RR and HR in the per-protocol analysis indicating an improved 
cardiac autonomic tone in these patients. The beneficial effect on cardiac autonomic 
tone and NSAID-sparing effect of n-3 PUFA could be advantageous in patients with 
PsA with increased risk of CVD. However, we were unable to demonstrate any 
changes in BP, PWV, central BP and AIx measurements. The participating patients 
with PsA had a low disease activity and the results might be different in newly 
diagnosed patients or patients with high disease activity.  
In conclusion, n-3 PUFA supplementation in patients with PsA might reduce the 
inflammatory processes and provide cardioprotection. The large number of 
participants completing the study underlines its applicability to real practice settings 
and n-3 PUFA might be an attractive adjunctive treatment in patients with PsA. 
However, further long-term studies are required to demonstrate whether the effect on 
RR and HR translates into a reduction of CVD in patients with PsA. Large-scale 
studies are also needed to evaluate the potential effect of n-3 PUFA on disease activity 
outcome measures. 
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This thesis is based on three studies of patients with established psoriatic arthritis (PsA) aiming 
at investigating the effect of marine n-3 polyunsaturated fatty acids (PUFA) on clinical symp-
toms and selected measures of inflammation, cardiac autonomic and hemodynamic function in 
these patients.
Study I aimed to investigate whether training in standardised assessment of enthesitis in PsA is 
able to improve interobserver variation. Furthermore, ultrasonography (US) and clinical assess-
ment of enthesitis were compared in detecting abnormalities. The results of this study showed 
significant reduction in interobserver variation with training in standardised enthesitis scoring 
systems, suggesting training sessions of clinicians before assessment of enthesitis in daily prac-
tice. US revealed more advanced stages of enthesitis, such as enthesophytes and erosions, which 
were not detected by clinical examination. 
To investigate effects of marine n-3 PUFA on clinical outcomes, important biochemical markers 
and cardiovascular risk in patients with PsA a randomized placebo-controlled trial was under-
taken (Study II and III). One-hundred and forty-five patients were enrolled and randomized to a 
supplement with either 3 g of marine n-3 PUFA (6 capsules of fish oil) or 3 g of olive oil daily 
for 24 weeks. A total of 133 patients (92%) completed the study. The difference in the outcomes 
between baseline and 24 weeks was analysed within and between the two supplemented groups.
In Study II, the effects of n-3 PUFA supplementation on outcome measures for disease activ-
ity, NSAID and paracetamol consumption and inflammation quantified as leukotriene forma-
tion from stimulated granulocytes was examined. The n-3 PUFA supplemented group showed 
improvement in outcome measures for disease activity, though without reaching a significant 
difference between the groups. However, use of NSAID and paracetamol was significantly re-
duced from baseline to week 24 in the n-3 PUFA group; also when compared with the control 
group. Furthermore, there was a significant decrease in leukotriene B4 (LTB4) formation from 
activated granulocytes in the n-3 PUFA group compared with controls. The results indicate a 
beneficial effect of n-3 PUFA on joint inflammation and pain.
In Study III, the aim was to investigate the effect of marine n-3 PUFA on cardiac autonomic func-
tion assessed by heart rate variability (HRV), blood pressure (BP), pulse wave velocity (PWV) 
and central BP. After 24 weeks of supplementation, there was a trend towards increase in HRV 
in the intention to treat analysis and a significant increase in HRV in the compliant patients. 
This finding may suggest a protective effect of n-3 PUFA against cardiovascular disease in this 
population. There were, however, no changes in BP, PWV or central BP between supplements.
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